#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Significance of immunotherapy with anti-CD20 rituximab and high-dose chemotherapy with autologous peripheral blood stem-cell transplantation in first-line treatment for mantle-cell lymphoma – centre experience


Authors: S. Vokurka;  V. Koza;  P. Jindra;  K. Steinerová;  V. Vozobulová;  M. Schutzova;  D. Lysák;  M. Švojgrová;  L. Mohammad;  M. Karas;  T. Svoboda
Authors‘ workplace: Hematologicko-onkologické oddělení, Fakultní nemocnice v Plzni
Published in: Transfuze Hematol. dnes,12, 2006, No. 4, p. 240-243.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Mantle cell lymphoma is a lymphoid neoplasia with unfavorable prognosis, incurable by means of conventional chemotherapy. In 48 patients suffering with this lymphoma an effect of induction chemotherapy (CHOP-21 or intensified anthracyclines-based regimen by Th.Waits in 20/48 patients, CHOP-21 with sequential imunotherapy anti-CD20 rituximab in 18/48 and VAD+chlorambucil in 10/48) and an effect of autologous peripheral blood stem cells transplantation in 19/48 patients were analyzed. Complete remission was more often reached in CHOP induction regimen followed with anti-CD20 immunotherapy in comparison to anthracyclines-based regimens without anti-CD20 or compared to VAD+chlorambucil protocol (77 % vs. 30 % vs. 10 %, p = 0,011). The autologous transplantation further improved the number of complete remissions from 47 % to 94 %. With the median follow-up of 41 (12–116) months, in the whole cohort of patients, 79 % of patients relapsed/progressed with the median time to relaps/progression of 20 (2–66) months, and 59 % of patients died with the median overall survival of 30 (1–81) months. Despite intensified first-line treatment with autologous stem cell transplantation and addition of anti-CD20 immunotherapy, the prognosis of mantle cell lymphoma patients remains poor.

Key words:
mantle cell lymphoma, autologous transplantation, chemotherapy, rituximab


Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 4

2006 Issue 4

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#